Groupon trimmed marketing costs in the second-quarter but its loss more than doubled as it hired new employees, the Internet daily deals company said in an update filing for its IPO.
Global brewer SABMiller is set to renew its assault on Australian bid target Foster’s later this month with a slightly higher offer likely to succeed after rival bidders fail to appear, bankers and investors told Reuters.
HSBC is nearing a deal to sell its $30 billion-plus U.S. credit card business to Capital One, sources familiar with the situation said.
Investors who bet big money on the outcome of merger and acquisition deals are scurrying as a plunging stock market jeopardizes many transactions.
Shares in reinsurer Transatlantic Holdings rose more than 8 percent on Monday despite broad and deep market declines, after Warren Buffett’s Berkshire Hathaway made an unsolicited offer over the weekend to buy the company. The NYT looks at the chances of the deal getting done.
As broad economic worries pound the markets, a growing number of IPOs are being delayed or pulled. Tech IPOs, whose multibillion valuations recall the heady days of the dotcom boom of the late 90s and early 2000s, might fall the furthest.
Kraft’s split is the latest in what is shaping up to be the year of the spin-off, and multiplying banker fees.
Kraft said it would split itself into two listed companies, a global snacks business and a North American grocery business, and raised its full-year outlook on better-than-expected quarterly results.
Hitachi and Mitsubishi Heavy Industries have begun talks on what would be Japan’s biggest domestic merger, three sources said, heralding a long awaited shake-up of the nation’s industrial behemoths. Japan Real Time reports on the clumsy merger kabuki which followed a leak to local media.
A examination of a cross-section of 122 Chinese reverse mergers on U.S. markets found that between each stock’s peak trading price and July 10, 2011, those companies saw a total of $18 billion of their market capitalization vanish. Reuters is exploring the extent and impact of corporate secrecy in the United States in a series of articles.
Expect more hostile deals in resources as cashed-up miners turn desperate to snare targets, deal advisers say, following Peabody Energy and ArcelorMittal’s change of tack this week on their $5.3 billion bid for Macarthur Coal.
Hong Kong tycoon Li Ka-shing has agreed to buy British utility Northumbrian Water Group for $3.9 billion in the biggest takeover this year of a British-listed company. Analysts at UBS predicted Li would seize other acquisition opportunities as cash-strapped investors and governments seek to cut their debt piles by selling infrastructure assets.
Japan’s Kirin is buying a controlling stake in major Brazilian beer and soft drinks maker Schincariol for $2.6 billion, making its first foray in the fast-growing South American economy.
For a self-described nerdy accountant who shuns attention, Express Scripts chief George Paz just thrust himself into the limelight, reports Lewis Krauskopf. The company’s planned buy of Medco Health Solutions met with swift opposition from consumer advocates and drug stores, signaling the beginning of what could be an ugly fight for antitrust approval.
Len Blavatnik’s Access Industries, Sony Music Entertainment and Vivendi SA’s Universal Music Group are among the music companies and private equity firms interested in buying EMI Group, people familiar with the situation said.
Express Scripts will buy rival Medco Health Solutions for $29.1 billion in cash and stock to create a powerhouse in managing prescription drug benefits in the United States, the companies said on Thursday. The WSJ live blogged the companies’ conference call on the merger.
Two Chinese Internet firms have postponed their U.S. fundraising plans due to volatile global markets and after a series of accounting scandals tarnished the reputation of overseas-listed Chinese companies.
Carl Icahn raised his offer to buy household products maker Clorox to $80 a share from $76.50 after the company rejected his previous offer as too low and not credible.
Icahn’s bid for Clorox has “rekindled the long-running debate about whether investors benefit from Mr. Icahn’s presence,” writes the NYT’s Deal Professor.
The London Stock Exchange has boosted its chances of avoiding the clutches of predatory rival Nasdaq OMX by reporting 14 percent growth as a standalone business. The Financial News reports the LSE is on the lookout for inorganic growth.